

Kenneth L Pitter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6917344/publications.pdf>

Version: 2024-02-01

35
papers

5,462
citations

218592

26
h-index

377752

34
g-index

35
all docs

35
docs citations

35
times ranked

9991
citing authors

#	ARTICLE	IF	CITATIONS
1	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. <i>Nature Medicine</i> , 2012, 18, 829-834.	15.2	1,029
2	BAX activation is initiated at a novel interaction site. <i>Nature</i> , 2008, 455, 1076-1081.	13.7	617
3	Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth. <i>Cell Stem Cell</i> , 2014, 14, 357-369.	5.2	411
4	A Stapled BID BH3 Helix Directly Binds and Activates BAX. <i>Molecular Cell</i> , 2006, 24, 199-210.	4.5	347
5	Dual role of proapoptotic BAD in insulin secretion and beta cell survival. <i>Nature Medicine</i> , 2008, 14, 144-153.	15.2	285
6	Corticosteroids compromise survival in glioblastoma. <i>Brain</i> , 2016, 139, 1458-1471.	3.7	271
7	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. <i>Science Translational Medicine</i> , 2015, 7, 274ra17.	5.8	257
8	Guiding Brain Tumor Resection Using Surface-Enhanced Raman Scattering Nanoparticles and a Hand-Held Raman Scanner. <i>ACS Nano</i> , 2014, 8, 9755-9766.	7.3	242
9	Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules. <i>Cell</i> , 2014, 156, 603-616.	13.5	241
10	Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. <i>Science Translational Medicine</i> , 2015, 7, 271ra7.	5.8	236
11	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. <i>Cancer Cell</i> , 2020, 38, 229-246.e13.	7.7	210
12	The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas. <i>Cancer Cell</i> , 2012, 22, 765-780.	7.7	179
13	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. <i>Journal of Clinical Investigation</i> , 2012, 122, 2018-2031.	3.9	153
14	In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5248-5253.	3.3	152
15	High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe. <i>Theranostics</i> , 2016, 6, 1075-1084.	4.6	96
16	Chapter 22 Synthesis and Biophysical Characterization of Stabilized α -Helices of BCL-2 Domains. <i>Methods in Enzymology</i> , 2008, 446, 369-386.	0.4	86
17	Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8149-8154.	3.3	80
18	A Membrane-targeted BID BCL-2 Homology 3 Peptide Is Sufficient for High Potency Activation of BAX in Vitro. <i>Journal of Biological Chemistry</i> , 2006, 281, 36999-37008.	1.6	74

#	ARTICLE	IF	CITATIONS
19	Astrocyte-Specific Expression Patterns Associated with the PDGF-Induced Glioma Microenvironment. PLoS ONE, 2012, 7, e32453.	1.1	67
20	Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma. PLoS ONE, 2011, 6, e14545.	1.1	64
21	The SHH/Gli pathway is reactivated in reactive glia and drives proliferation in response to neurodegeneration-induced lesions. Glia, 2014, 62, 1595-1607.	2.5	50
22	Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas. Glia, 2017, 65, 1914-1926.	2.5	50
23	Chapter 23 Dissection of the BCL-2 Family Signaling Network with Stabilized β -Helices of BCL-2 Domains. Methods in Enzymology, 2008, 446, 387-408.	0.4	44
24	Increased <i>HOXA5</i> expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes and Development, 2018, 32, 512-523.	2.7	40
25	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	3.0	38
26	Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma. Clinical Cancer Research, 2020, 26, 1135-1140.	3.2	33
27	Optimization of radiation dosing schedules for proneural glioblastoma. Journal of Mathematical Biology, 2016, 72, 1301-1336.	0.8	26
28	TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma. British Journal of Cancer, 2021, 125, 576-581.	2.9	26
29	Identification of Global Alteration of Translational Regulation in Glioma In Vivo. PLoS ONE, 2012, 7, e46965.	1.1	21
30	Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30670-30678.	3.3	11
31	Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer. Brachytherapy, 2018, 17, 621-627.	0.2	10
32	Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e279-e281.	0.2	8
33	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. Journal of Neuro-Oncology, 2019, 142, 523-528.	1.4	4
34	Anti-Leukemic Potency of Stapled BH3 Helices Correlates with Their Capacity for Bifunctional Activation of Apoptotic Pathways. Blood, 2006, 108, 711-711.	0.6	4
35	Structural Analysis of a BAX-BIM SAHB Complex Reveals a Novel BH3 Interaction Site on BAX for Therapeutic Activation of Apoptosis. Blood, 2008, 112, 300-300.	0.6	0